Dataset Information

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience.

ABSTRACT: Introduction Dose reductions are often required to avoid toxicity in combination therapy for advanced cancers, but information on appropriate dose reductions in renal dysfunction is lacking. This study assessed dose reductions of renally cleared oncology agents given in combination therapy in the setting of renal dysfunction. Methods A database of 1,072 patients was screened to identify patients with renal dysfunction (glomerular filtration rate < 60 mL/min) receiving oncology combination therapy with at least one agent requiring dose reduction for renal insufficiency. The dose of the renal agent was compared to the single-agent renal dosing recommendations to calculate a dose percentage. Tolerability was determined from electronic medical records review. Results Thirty-three regimens (n = 25 patients) were identified: 11 included at least one targeted agent (n = 8 patients) and 22 had only cytotoxic chemotherapy (n = 18 patients). The renal agent was given at the recommended single-agent renal dose in ~50% of combinations; ~50% of all regimens were tolerated, and only six combinations had dose reductions for toxicity. The median final dose percentage was 100% of the recommended renal dose (range: 25% - 333%); no significant differences were seen between groups (cytotoxic - tolerated, cytotoxic - not tolerated, targeted - tolerated, targeted - not tolerated; p = 0.38). No significant differences were observed between tolerated vs. non-tolerated (p = 0.97) or targeted vs. cytotoxic (p = 0.80) regimens. Conclusions Dose reductions of renally cleared agents are highly variable in oncology patients with renal dysfunction. Additional studies are needed to determine appropriate dosing adjustments in this population.

SUBMITTER: Nikanjam M

PROVIDER: S-EPMC6349570 | biostudies-other | 2018 Nov

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience.

Nikanjam Mina M Wing Jason J Capparelli Edmund E Kurzrock Razelle R

Cureus 20181126 11

Introduction Dose reductions are often required to avoid toxicity in combination therapy for advanced cancers, but information on appropriate dose reductions in renal dysfunction is lacking. This study assessed dose reductions of renally cleared oncology agents given in combination therapy in the setting of renal dysfunction. Methods A database of 1,072 patients was screened to identify patients with renal dysfunction (glomerular filtration rate < 60 mL/min) receiving oncology combination therap ...[more]

PMID: 30705793

Similar Datasets

Project description:BACKGROUND:Patients with rare tumors may lack approved treatments and clinical trial access. Although each rare tumor is uncommon, cumulatively they account for approximately 25% of cancers. We recently initiated a Rare Tumor Clinic that emphasized a precision medicine strategy. MATERIALS AND METHODS:We investigated the first 40 patients presenting at the Rare Tumor Clinic. Next-generation sequencing (NGS) of tissue and plasma-derived, circulating-tumor DNA (ctDNA), and protein markers were assessed. RESULTS:Median age was 58 years (range, 31-78 years); 70% (28/40) were women; median number of previous systemic therapies was 2 (range 0-7). The most common diagnoses were sarcoma (n?=?7) for solid tumors and Erdheim-Chester disease (n?=?5) for hematologic malignancies. Twenty distinct diagnoses were seen. Examples of ultrarare tumors included ameloblastoma, yolk sac liver tumor, ampullary cancer, and Castleman's disease. Altogether, 32 of 33 patients (97%) with tissue NGS and 15 of 33 (45%) with ctDNA sequencing harbored ?1 alteration. Overall, 92.5% of patients (37/40) had ?1 actionable target based on either genomic (n?=?32) or protein (n?=?27) markers. In total, 52.5% (21/40) received matched therapy; 52.4% (11/21) achieved stable disease (SD) ?6 months (n?=?3), partial remission (PR; n?=?6), or complete remission (CR; n?=?2). Matched therapy resulted in significantly longer progression-free survival compared with last prior unmatched therapy (hazard ratio 0.26, 95% confidence interval 0.10-0.71, p?=?.008). CONCLUSION:Identifying genomic and protein markers in patients with rare/ultrarare tumors was feasible. When therapies were matched, >50% of patients attained SD ?6 months, PR, or CR. Further precision medicine clinical investigations focusing on rare and ultrarare tumors are urgently needed. IMPLICATIONS FOR PRACTICE:Although rare tumors are infrequent by definition, when all subtypes of rare cancers are combined, they account for approximately 25% of adult malignancies. However, patients with rare tumors may lack approved treatments and clinical trial access. This paper describes an institutional a Rare Tumor Clinic focused on a precision medicine strategy. Performing genomics and protein analyses was feasible amongst patients with rare cancers. Over 50% of patients attained SD ?6 months, PR, or CR when they received matched therapy (genomically targeted and/or immunotherapy). Further studies investigating the efficacy of the precision therapy approach among rare tumors are warranted.

Project description:BackgroundThe diversity in the genomic landscape of advanced and metastatic tumors calls for combination therapies based on the genomic signature associated with each tumor. Determining safe and tolerable doses for novel combinations of oncology drugs is essential for a precision medicine approach, but can also require dose reductions. Trametinib, palbociclib, and everolimus are among the targeted therapies most often used in novel combinations at our precision medicine clinic.ObjectiveTo evaluate the safe, tolerable dosing of trametinib, palbociclib, and everolimus when used as part of novel combinations with other agents for the treatment of advanced or metastatic solid tumors.MethodsThis retrospective study included adult patients with advanced or metastatic solid tumors who received trametinib, everolimus, or palbociclib plus other therapies as a part of novel combinations between December 2011 and July 2018 at the University of California San Diego. Patients were excluded if they received trametinib, everolimus, or palbociclib in standard combinations, such as dabrafenib plus trametinib, everolimus plus fulvestrant, everolimus plus letrozole, and palbociclib plus letrozole. Dosing and adverse events were determined through a review of the electronic medical records. A safe, tolerable drug combination dose was defined as being tolerated for at least 1 month, with no clinically significant serious adverse events.ResultsA safe, tolerable dose was determined for 76% of the 71 patients who received trametinib, 88% of the 48 patients who received everolimus, and 73% of the 41 patients receiving palbociclib when used in combination with other therapies. For patients with clinically significant adverse events, dose reductions were attempted in 30% of the trametinib recipients, in 17% of everolimus recipients, and in 45% of palbociclib recipients. When used in combination with other therapies, the optimal dosing of trametinib, palbociclib, and everolimus was lower than the standard single-agent dosing: it was 1 mg daily for trametinib; 5 mg daily for everolimus; and 75 mg daily, for 3 weeks on and 1 week off for palbociclib. Of note, everolimus could not be given concomitantly with trametinib at these doses.ConclusionSafe and tolerable dosing of novel combination therapies that includes trametinib, everolimus, or palbociclib is feasible for a precision medicine approach. However, neither results from this study nor results from previous studies could support the use of everolimus in combination with trametinib, even at reduced doses.

Project description:The Pacific coast tick, Dermacentor occidentalis Marx, is found throughout California and can harbor agents that cause human diseases such as anaplasmosis, ehrlichiosis, tularemia, Rocky Mountain spotted fever and rickettsiosis 364D. Previous studies have demonstrated that nonpathogenic endosymbiotic bacteria can interfere with Rickettsia co-infections in other tick species. We hypothesized that within D. occidentalis ticks, interference may exist between different nonpathogenic endosymbiotic or nonendosymbiotic bacteria and Spotted Fever group Rickettsia (SFGR). Using PCR amplification and sequencing of the rompA gene and intergenic region we identified a cohort of SFGR-infected and non-infected D. occidentalis ticks collected from San Diego County. We then amplified a partial segment of the 16S rRNA gene and used next-generation sequencing to elucidate the microbiomes and levels of co-infection in the ticks. The SFGR R. philipii str. 364D and R. rhipicephali were detected in 2.3% and 8.2% of the ticks, respectively, via rompA sequencing. Interestingly, next generation sequencing revealed an inverse relationship between the number of Francisella-like endosymbiont (FLE) 16S rRNA sequences and Rickettsia 16S rRNA sequences within individual ticks that is consistent with partial interference between FLE and SFGR infecting ticks. After excluding the Rickettsia and FLE endosymbionts from the analysis, there was a small but significant difference in microbial community diversity and a pattern of geographic isolation by distance between collection locales. In addition, male ticks had a greater diversity of bacteria than female ticks and ticks that weren't infected with SFGR had similar microbiomes to canine skin microbiomes. Although experimental studies are required for confirmation, our findings are consistent with the hypothesis that FLEs and, to a lesser extent, other bacteria, interfere with the ability of D. occidentalis to be infected with certain SFGR. The results also raise interesting possibilities about the effects of putative vertebrate hosts on the tick microbiome.

Dataset Information

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience.

Publications

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets